{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:50:09Z","timestamp":1787273409032,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01797-9","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:15:10Z","timestamp":1781010910000},"page":"3961-3977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Luciano","family":"Ibba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Di Giulio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Balato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Bardazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Travaglini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Girolomoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maurelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Burlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Caccavale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo G.","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Carugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Dapavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia V.","family":"Di Brizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca M.","family":"Gaiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lasagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Loconsole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Potestio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Sacchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zerbinati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9263","authenticated-orcid":false,"given":"Mario","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"issue":"4","key":"1797_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-02846-z","volume":"316","author":"K Wang","year":"2024","unstructured":"Wang K, Zhao Y, Cao X. Global burden and future trends in psoriasis epidemiology: insights from the Global Burden of Disease Study 2019 and predictions to 2030. Arch Dermatol Res. 2024;316(4):114. https:\/\/doi.org\/10.1007\/s00403-024-02846-z.","journal-title":"Arch Dermatol Res"},{"key":"1797_CR2","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v105.42945","volume":"105","author":"C Skayem","year":"2025","unstructured":"Skayem C, Taieb C, Halioua B, Baissac C, Saint Aroman M. Epidemiology of psoriasis: a worldwide global study. Acta Derm Venereol. 2025;105:adv42945. https:\/\/doi.org\/10.2340\/actadv.v105.42945.","journal-title":"Acta Derm Venereol"},{"issue":"19","key":"1797_CR3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA"},{"issue":"3","key":"1797_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","volume":"21","author":"A Raharja","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med. 2021;21(3):170\u20133. https:\/\/doi.org\/10.7861\/clinmed.2021-0257.","journal-title":"Clin Med"},{"issue":"4-5","key":"1797_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.autrev.2014.01.008","volume":"13","author":"SK Raychaudhuri","year":"2014","unstructured":"Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmun Rev. 2014;13(4\u20135):490\u20135. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.008.","journal-title":"Autoimmun Rev"},{"issue":"22","key":"1797_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216095","volume":"24","author":"AM Man","year":"2023","unstructured":"Man AM, Or\u0103san MS, Hoteiuc OA, Ol\u0103nescu-Vaida-Voevod MC, Mocan T. Inflammation and psoriasis: a comprehensive review. Int J Mol Sci. 2023;24(22):16095. https:\/\/doi.org\/10.3390\/ijms242216095.","journal-title":"Int J Mol Sci"},{"issue":"13","key":"1797_CR7","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.2169\/internalmedicine.56.8209","volume":"56","author":"M Furue","year":"2017","unstructured":"Furue M, Tsuji G, Chiba T, Kadono T. Cardiovascular and metabolic diseases comorbid with psoriasis: beyond the skin. Intern Med. 2017;56(13):1613\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.56.8209.","journal-title":"Intern Med"},{"issue":"11","key":"1797_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9111511","volume":"9","author":"A Campanati","year":"2021","unstructured":"Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A. Psoriasis as an immune-mediated and inflammatory systemic disease: from pathophysiology to novel therapeutic approaches. Biomedicines. 2021;9(11):1511. https:\/\/doi.org\/10.3390\/biomedicines9111511.","journal-title":"Biomedicines"},{"key":"1797_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56719-8","volume":"16","author":"N Dand","year":"2025","unstructured":"Dand N, Stuart PE, Bowes J, et\u00a0al. GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. Nat Commun. 2025;16:2051. https:\/\/doi.org\/10.1038\/s41467-025-56719-8.","journal-title":"Nat Commun"},{"issue":"2","key":"1797_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.gene.6364046","volume":"5","author":"K Kingo","year":"2004","unstructured":"Kingo K, K\u00f5ks S, Nikopensius T, Silm H, Vasar E. Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes Immun. 2004;5(2):117\u201321. https:\/\/doi.org\/10.1038\/sj.gene.6364046.","journal-title":"Genes Immun"},{"issue":"5","key":"1797_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/sj.gene.6364216","volume":"6","author":"S K\u00f5ks","year":"2005","unstructured":"K\u00f5ks S, Kingo K, Vabrit K, et\u00a0al. Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes Immun. 2005;6(5):407\u201315. https:\/\/doi.org\/10.1038\/sj.gene.6364216.","journal-title":"Genes Immun"},{"key":"1797_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2147\/PTT.S519420","volume":"15","author":"M Ponikowska","year":"2025","unstructured":"Ponikowska M, Vellone E, Czapla M, Uchmanowicz I. Challenges: psoriasis and its impact on quality of life: challenges in treatment and management. Psoriasis Targets Ther. 2025;15:175\u201383. https:\/\/doi.org\/10.2147\/PTT.S519420.","journal-title":"Psoriasis Targets Ther"},{"issue":"1","key":"1797_CR13","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2425029","volume":"35","author":"L Ibba","year":"2024","unstructured":"Ibba L, Di Giulio S, Gargiulo L, et\u00a0al. Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study. J Dermatolog Treat. 2024;35(1):2425029. https:\/\/doi.org\/10.1080\/09546634.2024.2425029.","journal-title":"J Dermatolog Treat"},{"key":"1797_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1659346","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Xing J, Liang Y, et\u00a0al. The complex interplay between psoriasis and depression: from molecular mechanisms to holistic treatment approaches. Front Immunol. 2025;16:1659346. https:\/\/doi.org\/10.3389\/fimmu.2025.1659346.","journal-title":"Front Immunol"},{"issue":"11","key":"1797_CR15","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1468-3083.2010.03965.x","volume":"25","author":"A Tadros","year":"2011","unstructured":"Tadros A, Vergou T, Stratigos AJ, et\u00a0al. Psoriasis: is it the tip of the iceberg for the quality of life of patients and their families? J Eur Acad Dermatol Venereol. 2011;25(11):1282\u20137. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03965.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1797_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2199108","volume":"34","author":"L Ibba","year":"2023","unstructured":"Ibba L, Gargiulo L, Alfano A, et\u00a0al. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study. J Dermatolog Treat. 2023;34(1):2199108. https:\/\/doi.org\/10.1080\/09546634.2023.2199108.","journal-title":"J Dermatolog Treat"},{"key":"1797_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.649408","volume":"8","author":"BX Yan","year":"2021","unstructured":"Yan BX, Chen XY, Ye LR, Chen JQ, Zheng M, Man XY. Cutaneous and systemic psoriasis: classifications and classification for the distinction. Front Med. 2021;8:649408. https:\/\/doi.org\/10.3389\/fmed.2021.649408.","journal-title":"Front Med"},{"issue":"Suppl. 1 to No.","key":"1797_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23736\/S2784-8671.21.07132-2","volume":"157","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Fargnoli MC, Amerio P, et\u00a0al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venereol. 2022;157(Suppl. 1 to No. 1):1\u201378. https:\/\/doi.org\/10.23736\/S2784-8671.21.07132-2.","journal-title":"Ital J Dermatol Venereol"},{"issue":"11","key":"1797_CR19","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","volume":"34","author":"A Nast","year":"2020","unstructured":"Nast A, Smith C, Spuls PI, et\u00a0al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461\u201398. https:\/\/doi.org\/10.1111\/jdv.16915.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1797_CR20","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s13555-025-01474-3","volume":"15","author":"B Strober","year":"2025","unstructured":"Strober B, Patel M, Kaldas MI, et\u00a0al. Real-world skin clearance and quality of life with risankizumab in patients with psoriasis with moderate skin involvement and those eligible for systemic therapy per International Psoriasis Council Classification. Dermatol Ther. 2025;15(9):2409\u201321. https:\/\/doi.org\/10.1007\/s13555-025-01474-3.","journal-title":"Dermatol Ther"},{"issue":"7","key":"1797_CR21","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s13555-025-01423-0","volume":"15","author":"MG Lebwohl","year":"2025","unstructured":"Lebwohl MG, Carvalho A, Asahina A, et\u00a0al. Biologics for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. Dermatol Ther. 2025;15(7):1633\u201356. https:\/\/doi.org\/10.1007\/s13555-025-01423-0.","journal-title":"Dermatol Ther"},{"key":"1797_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/PTT.S356568","volume":"12","author":"CC de Ruiter","year":"2022","unstructured":"de Ruiter CC, Rustemeyer T. Biologics can significantly improve Dermatology Life Quality Index (DLQI) in psoriatic patients: a systematic review. Psoriasis Targets Ther. 2022;12:99\u2013112. https:\/\/doi.org\/10.2147\/PTT.S356568.","journal-title":"Psoriasis Targets Ther"},{"key":"1797_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub7","author":"E Sbidian","year":"2025","unstructured":"Sbidian E, Chaimani A, Guelimi R, et\u00a0al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2025. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub7.","journal-title":"Cochrane Database Syst Rev"},{"key":"1797_CR24","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S540848","volume":"19","author":"M Megna","year":"2026","unstructured":"Megna M, D\u2019Agostino M, Feo F, Ventura V, Tommasino N, Potestio L. IL-23 inhibitors in psoriasis: what have we learnt so far? J Inflamm Res. 2026;19:540848. https:\/\/doi.org\/10.2147\/JIR.S540848.","journal-title":"J Inflamm Res"},{"issue":"18","key":"1797_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14186371","volume":"14","author":"S Di Giulio","year":"2025","unstructured":"Di Giulio S, Falcidia C, Foggi G, et\u00a0al. Predictors of super-responder status to anti-IL-23 therapies in moderate-to-severe plaque psoriasis: a real-world monocenter study. J Clin Med. 2025;14(18):6371. https:\/\/doi.org\/10.3390\/jcm14186371.","journal-title":"J Clin Med"},{"issue":"11","key":"1797_CR26","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/1744666X.2020.1679625","volume":"15","author":"K Ly","year":"2019","unstructured":"Ly K, Smith MP, Thibodeaux Q, Reddy V, Liao W, Bhutani T. Anti IL-17 in psoriasis. Expert Rev Clin Immunol. 2019;15(11):1185\u201394. https:\/\/doi.org\/10.1080\/1744666X.2020.1679625.","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"1797_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40257-025-00928-w","volume":"26","author":"D Kim","year":"2025","unstructured":"Kim D, Yang S, Gill M, Babaei N, Cervantes M, Wu JJ. Next-generation anti-IL-17 agents for psoriatic disease: a pipeline review. Am J Clin Dermatol. 2025;26(3):307\u201320. https:\/\/doi.org\/10.1007\/s40257-025-00928-w.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1797_CR28","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, et\u00a0al. Secukinumab in plaque psoriasis\u2014results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1314258.","journal-title":"N Engl J Med"},{"issue":"14","key":"1797_CR29","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, et\u00a0al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1412679.","journal-title":"N Engl J Med"},{"issue":"9999","key":"1797_CR30","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, et\u00a0al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(15)61134-5.","journal-title":"Lancet"},{"issue":"10378","key":"1797_CR31","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Jemec GBE, Alavi A, et\u00a0al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(23)00022-3.","journal-title":"Lancet"},{"key":"1797_CR32","unstructured":"Cosentyx | European Medicines Agency (EMA). June 7, 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cosentyx. Accessed 19 Feb 2026."},{"issue":"9","key":"1797_CR33","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.14878","volume":"32","author":"R Bissonnette","year":"2018","unstructured":"Bissonnette R, Luger T, Tha\u00e7i D, et\u00a0al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE extension study). J Eur Acad Dermatol Venereol. 2018;32(9):1507\u201314. https:\/\/doi.org\/10.1111\/jdv.14878.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1797_CR34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/bjd\/ljac040","volume":"188","author":"RG Langley","year":"2023","unstructured":"Langley RG, Sofen H, Dei-Cas I, et\u00a0al. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023;188(2):198\u2013207. https:\/\/doi.org\/10.1093\/bjd\/ljac040.","journal-title":"Br J Dermatol"},{"issue":"7","key":"1797_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14070718","volume":"14","author":"L Mastorino","year":"2024","unstructured":"Mastorino L, Dapavo P, Cariti C, et\u00a0al. Drug survival, safety, and effectiveness of secukinumab for up to 5 years in patients with psoriasis and psoriatic arthritis: a long-term real-life experience. J Pers Med. 2024;14(7):718. https:\/\/doi.org\/10.3390\/jpm14070718.","journal-title":"J Pers Med"},{"issue":"6","key":"1797_CR36","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/jdv.16180","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, Jullien D, Martin A, Peralta C. Real-world evidence of secukinumab in psoriasis treatment\u2014a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020;34(6):1174\u201385. https:\/\/doi.org\/10.1111\/jdv.16180.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1797_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jaad.2019.02.031","volume":"81","author":"T Torres","year":"2019","unstructured":"Torres T, Balato A, Conrad C, et\u00a0al. Secukinumab drug survival in patients with psoriasis: a multicenter, real-world, retrospective study. J Am Acad Dermatol. 2019;81(1):273\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.031.","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"1797_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133864","volume":"13","author":"M Galluzzo","year":"2024","unstructured":"Galluzzo M, Trovato E, Talamonti M, et\u00a0al. Long-term persistence rate of secukinumab in psoriatic patients: a six-year multicenter, real-world experience, retrospective study. J Clin Med. 2024;13(13):3864. https:\/\/doi.org\/10.3390\/jcm13133864.","journal-title":"J Clin Med"},{"issue":"1","key":"1797_CR39","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2200868","volume":"34","author":"S Dastoli","year":"2023","unstructured":"Dastoli S, Passante M, Loconsole F, et\u00a0al. Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy. J Dermatolog Treat. 2023;34(1):2200868. https:\/\/doi.org\/10.1080\/09546634.2023.2200868.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1797_CR40","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s13555-024-01182-4","volume":"14","author":"M Valenti","year":"2024","unstructured":"Valenti M, Gargiulo L, Ibba L, et\u00a0al. Long-term effectiveness and safety of Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: a five-year multicenter retrospective study-IL PSO (Italian Landscape Psoriasis). Dermatol Ther. 2024;14(6):1649\u201357. https:\/\/doi.org\/10.1007\/s13555-024-01182-4.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1797_CR41","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/jdv.19682","volume":"38","author":"L Mastorino","year":"2024","unstructured":"Mastorino L, Dapavo P, Burzi L, et\u00a0al. Drug survival, effectiveness and safety of ixekizumab for moderate-to-severe psoriasis up to 5 years. J Eur Acad Dermatol Venereol. 2024;38(3):568\u201375. https:\/\/doi.org\/10.1111\/jdv.19682.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1797_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020495","volume":"13","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, et\u00a0al. Effectiveness, tolerability, and drug survival of Risankizumab in a real-world setting: a three-year retrospective multicenter study-IL PSO (Italian Landscape Psoriasis). J Clin Med. 2024;13(2):495. https:\/\/doi.org\/10.3390\/jcm13020495.","journal-title":"J Clin Med"},{"issue":"2","key":"1797_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000001064","volume":"37","author":"F Saeed","year":"2025","unstructured":"Saeed F, Adamopoulos IE. Pathogenesis of psoriatic arthritis: new insights from a bone marrow perspective. Curr Opin Rheumatol. 2025;37(2):136. https:\/\/doi.org\/10.1097\/BOR.0000000000001064.","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"1797_CR44","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1007\/s13555-025-01538-4","volume":"15","author":"R Ruiz-Villaverde","year":"2025","unstructured":"Ruiz-Villaverde R, Mateu A, Mendes-Bastos P, Torres T. Optimizing psoriasis treatment with tildrakizumab: current evidence and expert recommendations for treatment individualization in clinical practice. Dermatol Ther. 2025;15(11):3071\u201388. https:\/\/doi.org\/10.1007\/s13555-025-01538-4.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1797_CR45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/09546634.2019.1597245","volume":"31","author":"E Del Alc\u00e1zar","year":"2020","unstructured":"Del Alc\u00e1zar E, Ferran M, L\u00f3pez-Ferrer A, et\u00a0al. Effectiveness and safety of ustekinumab 90\u2009mg in patients weighing 100\u2009kg or less: a retrospective, observational, multicenter study. J Dermatolog Treat. 2020;31(3):222\u20136. https:\/\/doi.org\/10.1080\/09546634.2019.1597245.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1797_CR46","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2350760","volume":"35","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Cascio Ingurgio R, et\u00a0al. Comparative effectiveness of tildrakizumab 200\u2009mg versus tildrakizumab 100\u2009mg in psoriatic patients with high disease burden or above 90\u2009kg of body weight: a 16-week multicenter retrospective study\u2014IL PSO (Italian Landscape Psoriasis). J Dermatolog Treat. 2024;35(1):2350760. https:\/\/doi.org\/10.1080\/09546634.2024.2350760.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1797_CR47","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s13555-025-01416-z","volume":"15","author":"M Valenti","year":"2025","unstructured":"Valenti M, Ibba L, Di Giulio S, et\u00a0al. Optimizing tildrakizumab dosing in psoriasis: a 52-week multicenter retrospective study comparing 100 mg and 200 mg\u2014IL PSO (Italian Landscape Psoriasis). Dermatol Ther. 2025;15(6):1427\u201340. https:\/\/doi.org\/10.1007\/s13555-025-01416-z.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1797_CR48","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/14712598.2022.2029841","volume":"22","author":"M Galluzzo","year":"2022","unstructured":"Galluzzo M, Talamonti M, Atzori L, et\u00a0al. Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. Expert Opin Biol Ther. 2022;22(4):547\u201354. https:\/\/doi.org\/10.1080\/14712598.2022.2029841.","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"1797_CR49","doi-asserted-by":"publisher","first-page":"e626","DOI":"10.1111\/jdv.18087","volume":"36","author":"E Sotiriou","year":"2022","unstructured":"Sotiriou E, Bakirtzi K, Vakirlis E, et\u00a0al. Long-term drug survival of secukinumab in real life in the era of novel biologics: a 5-year, retrospective study, including difficult-to-treat areas. J Eur Acad Dermatol Venereol. 2022;36(8):e626\u20137. https:\/\/doi.org\/10.1111\/jdv.18087.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1797_CR50","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jaad.2025.05.1401","volume":"93","author":"KC Lauck","year":"2025","unstructured":"Lauck KC, Ahmed A, Davis MJ, Council ML, Nehal K, Alam M. Cutaneous malignancy after biologic therapy for inflammatory disease: an active comparator, retrospective cohort study. J Am Acad Dermatol. 2025;93(3):724\u201332. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1401.","journal-title":"J Am Acad Dermatol"},{"issue":"19","key":"1797_CR51","doi-asserted-by":"publisher","first-page":"17093","DOI":"10.1007\/s00432-023-05387-6","volume":"149","author":"JM Jung","year":"2023","unstructured":"Jung JM, Kim YJ, Chang SE, Lee MW, Won CH, Lee WJ. Cancer risks in patients with psoriasis administered biologics therapy: a nationwide population-based study. J Cancer Res Clin Oncol. 2023;149(19):17093\u2013102. https:\/\/doi.org\/10.1007\/s00432-023-05387-6.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1797_CR52","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.1982","volume":"102","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Dapavo P, Trunfio M, et\u00a0al. Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a tertiary care centre in Northern Italy. Acta Derm Venereol. 2022;102:adv00821. https:\/\/doi.org\/10.2340\/actadv.v102.1982.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"1797_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2241585","volume":"34","author":"L Ibba","year":"2023","unstructured":"Ibba L, Gargiulo L, Vignoli CA, et\u00a0al. Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study. J Dermatol Treat. 2023;34(1):2241585. https:\/\/doi.org\/10.1080\/09546634.2023.2241585.","journal-title":"J Dermatol Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01797-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01797-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:30:01Z","timestamp":1787243401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01797-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1797"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01797-9","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"4 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Luciano Ibba has been a consultant and\/or speaker and has served as an advisory board member for Almirall and LEO Pharma. Piergiorgio Malagoli has been a speaker for AbbVie, Eli Lilly, Novartis, Janssen-Cilag, Celgene, Leo Pharma, and Almirall. Anna Balato has received honoraria for participation in advisory boards, in meetings, or as a speaker for AbbVie, Celgene, Janssen-Cilag, Eli Lilly, Novartis Pharma, Pfizer, Sanofi-Genzyme, and UCB Pharma. Federico Bardazzi has been a consultant adviser and clinical study investigator for Eli Lilly, AbbVie, Novartis, Leo Pharma, Sandoz, Bristol Myers, Abiogen-Pharma, Celgene, and Janssen. Giampiero Girolomoni has received personal fees from AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli-Lilly, Janssen-Cilag, Leo Pharma, Merck Serono, Novartis, Pfizer, Pierre Fabre, Samsung Bioepis, and Sanofi. Martina Burlando has acted as a speaker and consultant for AbbVie, Janssen, Amgen, Novartis, Eli Lilly, and UCB Pharma. Carlo G. Carrera has served as a board participant or speaker for AbbVie, Eli Lilly, Janssen, Novartis, Celgene, Almirall, and Leo Pharma. Andrea Carugno has been a consultant and\/or speaker for AbbVie, Leo Pharma, Eli Lilly, Novartis, Janssen-Cilag, Amgen, Almirall, UCB Pharma, and Boehringer Ingelheim. Paolo Dapavo has been a speaker for Novartis, AbbVie, Sanofi, UCB, Janssen, Eli Lilly, and Leo Pharma. Claudio Guarneri has been a scientific consultant, speaker, and clinical study investigator for AbbVie, Celgene, Janssen, Eli Lilly, Novartis, Pfizer, Sanofi, Almirall, and Leo Pharma. Claudia Lasagni declares a conflict of interest with AbbVie, Novartis, Eli Lilly, and Almirall. Francesco Loconsole served on advisory boards and\/or received honoraria for lectures from AbbVie, Janssen-Cilag, Novartis, Lilly, and Sanofi. Angelo V. Marzano reports consultancy\/advisory boards disease-relevant honoraria from AbbVie, Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Incyte, Leopharma, Novartis, Pfizer, Sanofi, and UCB. Matteo Megna acted as a speaker or consultant for AbbVie, Eli Lilly, Janssen, Leo Pharma, and Novartis. Simone Ribero has served as an advisory board member and\/or consultant and has received fees and speaker\u2019s honoraria or has participated in clinical studies for AbbVie, Almirall, Leo Pharma, Eli Lilly, Novartis, Pfizer, and Sanofi Genzyme. Antonio Costanzo has served as an advisory board member, consultant, and has received fees and speaker\u2019s honoraria or has participated in clinical trials for AbbVie, Almirall, Biogen, Leo Pharma, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi Genzyme, and UCB Pharma. Alessandra Narcisi has served on advisory boards, received honoraria for lectures, and research grants from Almirall, AbbVie, Leo Pharma, Celgene, Eli Lilly, Janssen, Novartis, Sanofi Genzyme, Amgen, and Boehringer Ingelheim. Mario Valenti has been a consultant and\/or speaker for Sanofi, Leo Pharma, Eli Lilly, Novartis, Janssen, AbbVie, Boehringer Ingelheim, Almirall, UCB, and Difa Cooper. Sara Di Giulio, Martina Maurelli, Stefano Caccavale, Eugenia V. Di Brizzi, Valentina Dini, Francesca M. Gaiani, Luca Mastorino, Alessandra Michelucci, Lidia Sacchelli, Nicola Zerbinati, Luca Potestio, and Massimo Travaglini have nothing to declare. Mario Valenti is an Editorial Board Member of\u00a0\n                      Dermatology and Therapy\n                      . Mario Valenti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board approval was exempted, as the study protocol did not deviate from standard clinical practice. All patients received secukinumab as in good clinical practice, in accordance with Italian guidelines. All included patients had provided written consent for a retrospective study of data collected during routine clinical practice (demographics, clinical scores). The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Data collection and handling complied with applicable laws, regulations, and guidance regarding patient protection, including patient privacy.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}